Structure Therapeutics Inc. (GPCR)
USD 27.9
(-11.37%)
USD 27.9
(-11.37%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | 949.17 Thousand | 623.25 Thousand | 266.35 Thousand | 20.03 Thousand |
| Gross Profit | -949.17 Thousand | -623.25 Thousand | -266.35 Thousand | -20.03 Thousand |
| Operating Expenses | 102.77 Million | 52.56 Million | 37.69 Thousand | 15.9 Thousand |
| Selling, General and Administrative Expenses | 32.67 Million | 16.36 Million | 8585.00 | 3542.00 |
| Research and Development Expenses | 70.1 Million | 36.19 Million | 29.11 Thousand | 12.36 Thousand |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 102.77 Million | 52.56 Million | 37.69 Thousand | 15.9 Thousand |
| Operating Income | -102.77 Million | -52.56 Million | -37.69 Thousand | -15.9 Thousand |
| Interest Expense | 13.39 Million | - | 122.16 Thousand | - |
| Income Tax Expense | 236 Thousand | 17 Thousand | 231.00 | 138.00 |
| Earnings before Tax | -89.38 Million | -51.3 Million | -37.81 Thousand | -15.73 Thousand |
| Net Income | -89.62 Million | -51.32 Million | -38.04 Thousand | -15.87 Thousand |
| Earnings Per Share Basic | -2.44 | -1.40 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -2.44 | -1.40 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 36.73 Million | 36.58 Million | 36.58 Million | 36.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 36.73 Million | 36.58 Million | 36.58 Million | 36.58 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -102.45 Million | -52.28 Million | -37.62 Million | -15.74 Million |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.32 Million | - | - |
| Cost of Revenue | 231.73 Thousand | 658.92 Thousand | 949.17 Thousand | 280.91 Thousand | 351.02 Thousand | 160.26 Thousand |
| Gross Profit | -231.73 Thousand | -658.92 Thousand | -949.17 Thousand | 1.04 Million | -351.02 Thousand | -160.26 Thousand |
| Operating Expenses | 33.04 Million | 32.01 Million | 101.73 Million | 30.92 Million | 26.14 Million | 25.98 Million |
| Selling, General and Administrative Expenses | 11.02 Million | 11.33 Million | - | 10.74 Million | 8.63 Million | 6.57 Million |
| Research and Development Expenses | 22.02 Million | 20.67 Million | - | 20.17 Million | 17.51 Million | 19.41 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 33.27 Million | 32.01 Million | 102.68 Million | 31.2 Million | 26.14 Million | 25.98 Million |
| Operating Income | -33.27 Million | -32.01 Million | -102.68 Million | -31.2 Million | -26.14 Million | -25.98 Million |
| Interest Expense | - | 6 Million | 13.39 Million | 9.57 Million | 2.68 Million | 2.82 Million |
| Income Tax Expense | 52.93 Thousand | 29 Thousand | 235.79 Thousand | -314.14 Thousand | 405 Thousand | 118 Thousand |
| Earnings before Tax | -25.95 Million | -26 Million | -89.3 Million | -24.98 Million | -23.45 Million | -23.16 Million |
| Net Income | -26 Million | -26.03 Million | -89.54 Million | -24.67 Million | -23.86 Million | -23.28 Million |
| Earnings Per Share Basic | -0.53 | -0.56 | - | -0.53 | -0.62 | -0.61 |
| Earnings Per Share Diluted | -0.53 | -0.56 | - | -0.53 | -0.62 | -0.61 |
| Weighted Average Shares Outstanding | 49.41 Million | 46.57 Million | 36.73 Million | 46.4 Million | 38.31 Million | 38.25 Million |
| Weighted Average Shares Outstanding (Diluted) | 49.41 Million | 46.57 Million | 36.73 Million | 46.4 Million | 38.31 Million | 38.25 Million |
| Gross Margin | - | - | - | 0.79 | - | - |
| EBIT Margin | - | - | - | -23.25 | - | - |
| Profit Margin | - | - | - | -18.55 | - | - |
| EBITDA | -33.04 Million | -32.01 Million | - | -30.92 Million | -26.14 Million | -25.91 Million |
| Earnings Before Tax Margin | - | - | - | -23.46 | - | - |
1842
MISVF
LINRF
TTNM
RAD
CEN